Telectronics (US) starts implantable cardioverter defibrillator (ICD) trial as Angeion prepares for premarket approval (PMA)
This article was originally published in Clinica
Telectronics (US) has started clinical trials of its Sentry 4310 pectoral ICD (implantable cardioverter defibrillator) and EnGuard endocardial lead in Canada. The FDA has issued an IDE for ()the system and US clinical studies are expected to get under way soon. Meanwhile, Angeion is planning to file for US and German approval of its pectoral ICD this summer.